Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia

Leukemia. 2019 Oct;33(10):2531-2535. doi: 10.1038/s41375-019-0475-z. Epub 2019 May 14.

¹ Department of Internal Medicine III, Ulm University, 89081, Ulm, Germany. Stephan.Stilgenbauer@uniklinik-ulm.de.
² Department of Hematology, Institute Paoli-Calmettes, Marseille, France.
³ Department I of Internal Medicine, Center for Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany.
⁴ Department of Hematology/Oncology, Goethe University Hospital, Frankfurt am Main, Germany.
⁵ Universitair Ziekenhuis Gent, Gent, Belgium.
⁶ Département d'Hématologie Clinique, CHU Montpellier, Université Montpellier, 80 Avenue Augustin Fliche, 34295, Montpellier, France.
⁷ Antwerp University Hospital and University of Antwerp, Antwerp, Belgium.
⁸ Department of Hematology, Cliniques Universitaires Saint-Luc & Université Catholique de Louvain, B-1200, Brussels, Belgium.
⁹ IUCT-Oncopole, Toulouse, France.
¹⁰ Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, Germany.
¹¹ Department of Medicine V, University Hospital Heidelberg, Department of Molecular Therapy in Haematology & Oncology, NCT/DKFZ, Heidelberg, Germany.
¹² Department of Medical Oncology and Hematology, University Hospital Zürich and University of Zürich, Zürich, Switzerland.

No abstract available

Publication types